BMY stock climbed while AstraZeneca stock dropped after reports of merger talks that could create a nearly $400 billion drugmaker.
AstraZeneca Stock Falls While BMY Stock Jumps on Merger Talks
其他语言标题
- 한국어아스트라제네카 주가 하락, BMY 주가는 합병 논의로 급등
BMY stock climbed while AstraZeneca stock dropped after reports of merger talks that could create a nearly $400 billion drugmaker.